PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
Full Text:
FDA’s 2010 Drug
Safety Communication
Hartung, D. M., Middleton, L., Markwardt, S., Williamson, K
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma. The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization. METHODS: Using administrative data...
In the highly alkaline environment of concrete, carbon steel rebar is protected against corrosion by a passive oxide/oxyhydroxide film. Understanding the characteristics of this passive film, and how it depassivates, is the key for mitigating problems associated with steel corrosion in concrete. Although a large number of electrochemical and analytical...
BACKGROUND: Result summaries are now required to be reported in ClinicalTrials.gov for many 1 trials of drugs and
devices.
PURPOSE: To evaluate the consistency of reporting in trials that are both registered in the ClinicalTrials.gov results
database and published in the literature.
DATA SOURCES: ClinicalTrials.gov results database, matched publications identified...
Full Text:
Author
Acknowledgements: Luke Middleton, BS for developing abstraction tool and database. Kaylee